A Phase III Open-Label, Single-Arm, Multi-Center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients with Treatment-Naive or Pre-Treated Advanced Dedifferentiated Liposarcoma (Brightline-4)

Protocol No

BI-1403-0019-BRIGHTLINE-4

Phase

III

Summary

This study is being done to test the safety and effectiveness of the study drug, Brigimadlin, in subjects with DDLPS.

Brigimadlin has not been approved by the U.S. Food and Drug Administration (FDA) as a treatment for any disease and is experimental for this study.

Description

Study to test how well brigimadlin is tolerated by people with a type of cancer called dedifferentiated liposarcoma

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL